Nizatidine: Difference between revisions
Gareth CHEBI (talk | contribs) m ChEBI id added to Drugbox identifiers |
|||
| Line 38: | Line 38: | ||
| KEGG_Ref = {{keggcite|correct|kegg}} |
| KEGG_Ref = {{keggcite|correct|kegg}} |
||
| KEGG = D00440 |
| KEGG = D00440 |
||
| ChEBI_Ref = {{ebicite|correct|EBI}} |
|||
| ChEBI = 7601 |
|||
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
| ChEMBL_Ref = {{ebicite|correct|EBI}} |
||
| ChEMBL = 653 |
| ChEMBL = 653 |
||
Revision as of 16:07, 3 June 2014
 | |
| Clinical data | |
|---|---|
| Trade names | Axid |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a694030 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | >70% |
| Protein binding | 35% |
| Metabolism | Hepatic |
| Elimination half-life | 1-2 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.155.683 |
| Chemical and physical data | |
| Formula | C12H21N5O2S2 |
| Molar mass | 331.46 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It was developed by Eli Lilly and is marketed under the brand names Tazac and Axid.
Clinical use
Certain preparations of nizatidine are now available over the counter in various countries including the United States. Nizatidine has been used experimentally to control weight gain associated with some antipsychotic medication. [2]
Adverse effects
Antacid preparations such as nizatidine work by suppressing acid mediated break down of proteins, leads to an elevated risk of developing food or drug allergies. This happens due to undigested proteins then passing into the gastrointestinal tract where sensitisation occurs. It is unclear whether this risk occurs with only long-term use or with short-term use as well.[3]
History and development
Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole-ring in place of the furan-ring in ranitidine. In September 2000 Eli Lilly announced they would sell the sales and marketing rights for Axid to Reliant Pharmaceuticals. [4] Subsequently, Reliant developed the oral solution of Axid, marketing this in 2004, after gaining approval from the U.S. Food and Drug Administration (FDA). [5] However, a year later they sold rights of the Axid Oral Solution (including the issued patent US6,930,119 protecting the product) to Braintree Laboratories.[6]
Nizatidine proved to be the last new histamine H2-receptor antagonist introduced prior to the advent of proton pump inhibitors.
See also
- Famotidine, aka Pepcid AC, Pepcidine: another popular H2-receptor antagonist
References
- ^ Nizatidine
- ^ Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Kilic N (January 2004). "Nizatidine for the treatment of patients with quetiapine-induced weight gain". Hum Psychopharmacol. 19 (1): 37–40. doi:10.1002/hup.477. PMID 14716710.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Pali-Schöll I, Jensen-Jarolim E (April 2011). "Anti-acid medication as a risk factor for food allergy". Allergy. 66 (4): 469–77. doi:10.1111/j.1398-9995.2010.02511.x. PMID 21121928.
- ^ Eli Lilly and Company and Reliant Pharmaceuticals Announce
- ^ Reliant Pharmaceuticals : Press Releases
- ^ Reliant Pharmaceuticals : Press Releases